Alexandria, VA – August 29, 2023 – The Innovation and Value Initiative (IVI), a non-profit research organization committed to advancing the science, practice, and use of health technology assessment in health care, today issued a statement in response to the Centers for Medicare and Medicaid Services’ (CMS) announcement of the first prescription drugs selected for price negotiations under the Inflation Reduction Act (IRA).

The following statement is attributed to Jason Spangler, MD, MPH, FACPM, CEO of the Innovation and Value Initiative (IVI):

“CMS must ensure that patient-centered priorities are a driving consideration in the development and implementation of the Drug Pricing Negotiation Program (DPNP). Patient engagement is essential and can provide valuable insights into the benefits and risks of treatments, as well as their experiences with the healthcare system. CMS should address the health equity challenges of engaging marginalized patient populations which are often underrepresented in clinical trials and other research studies, as well as consider incorporating real world evidence into the DPNP program to provide insights into the effectiveness and safety of treatments in real-world settings. By prioritizing patient input and experience and advancing health equity when developing and implementing the DPNP program, CMS will ensure that the program is effective and beneficial to all patients, including those who are marginalized or underrepresented.”


About IVI
The Innovation and Value Initiative (IVI) is a 501(c)(3) tax-exempt, non-profit research organization dedicated to advancing the science and improving the practice of health technology assessment through development of novel methods and the creation and application of enhanced health technology assessment models to support local decision-making needs in healthcare.

Contact: Smita Sanwardeker
Phone: 267.909.7661